Our findings show that lack of CB1R exerts a hepatoprotective effect and raises the possibility of using CB1R-specific antagonists or inverse agonists to mitigate against hepatitis during acute toxin injury. The gene discussed is CNR1; the disease is hepatitis A virus infection.